4.58
price up icon6.02%   0.26
 
loading
Nevro Corp stock is traded at $4.58, with a volume of 331.92K. It is up +6.02% in the last 24 hours and up +0.00% over the past month. Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
See More
Previous Close:
$4.32
Open:
$4.34
24h Volume:
331.92K
Relative Volume:
0.62
Market Cap:
$166.56M
Revenue:
$425.17M
Net Income/Loss:
$-92.21M
P/E Ratio:
458.00
EPS:
0.01
Net Cash Flow:
$-67.42M
1W Performance:
+8.27%
1M Performance:
+0.00%
6M Performance:
-51.22%
1Y Performance:
-72.26%
1-Day Range:
Value
$4.34
$4.61
1-Week Range:
Value
$4.20
$4.82
52-Week Range:
Value
$3.95
$22.64

Nevro Corp Stock (NVRO) Company Profile

Name
Name
Nevro Corp
Name
Phone
650-251-0005
Name
Address
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Name
Employee
1,215
Name
Twitter
@Nevro_HF10
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
NVRO's Discussions on Twitter

Compare NVRO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
NVRO
Nevro Corp
4.58 166.56M 425.17M -92.21M -67.42M 0.01
Medical Devices icon
ABT
Abbott Laboratories
118.95 208.18B 41.22B 5.77B 6.49B 2.94
Medical Devices icon
SYK
Stryker Corp
388.14 148.70B 21.97B 3.59B 3.21B 6.74
Medical Devices icon
BSX
Boston Scientific Corp
90.75 133.32B 15.91B 1.79B 1.89B 0.82
Medical Devices icon
MDT
Medtronic Plc
86.27 111.27B 33.00B 4.29B 5.50B 2.71
Medical Devices icon
EW
Edwards Lifesciences Corp
72.07 42.66B 6.60B 4.16B 490.10M 2.34

Nevro Corp Stock (NVRO) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-09-24 Upgrade Citigroup Sell → Neutral
Aug-08-24 Upgrade Wolfe Research Underperform → Peer Perform
Aug-07-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-07-24 Downgrade JP Morgan Neutral → Underweight
Aug-07-24 Downgrade Wells Fargo Equal Weight → Underweight
May-22-24 Downgrade Citigroup Neutral → Sell
Feb-22-24 Downgrade Oppenheimer Outperform → Perform
Jan-12-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-21-23 Downgrade Canaccord Genuity Buy → Hold
Jul-19-23 Initiated Robert W. Baird Neutral
May-31-23 Initiated RBC Capital Mkts Outperform
May-15-23 Upgrade Oppenheimer Perform → Outperform
Apr-14-23 Initiated Mizuho Neutral
Jan-17-23 Downgrade Citigroup Buy → Neutral
Jan-06-23 Downgrade Piper Sandler Neutral → Underweight
Dec-20-22 Upgrade Canaccord Genuity Hold → Buy
Dec-12-22 Downgrade Wells Fargo Overweight → Equal Weight
Oct-12-22 Initiated Jefferies Underperform
May-05-22 Upgrade Citigroup Neutral → Buy
Apr-13-22 Resumed Truist Hold
Apr-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Underperform
Jan-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-06-21 Upgrade Wells Fargo Equal Weight → Overweight
Nov-09-21 Downgrade Truist Buy → Hold
Aug-05-21 Downgrade Canaccord Genuity Buy → Hold
Aug-05-21 Downgrade Citigroup Buy → Neutral
Aug-05-21 Downgrade Piper Sandler Overweight → Neutral
Aug-05-21 Downgrade Wells Fargo Overweight → Equal Weight
Aug-05-21 Downgrade William Blair Outperform → Mkt Perform
Jul-09-21 Downgrade Redburn Buy → Neutral
Jul-06-21 Downgrade Robert W. Baird Outperform → Neutral
Feb-02-21 Initiated Piper Sandler Overweight
Oct-23-20 Initiated Guggenheim Buy
Sep-02-20 Initiated Robert W. Baird Outperform
Jun-08-20 Upgrade UBS Sell → Neutral
Mar-05-20 Initiated Citigroup Buy
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Jan-08-20 Initiated SunTrust Buy
Jan-06-20 Downgrade Oppenheimer Outperform → Perform
Nov-07-19 Upgrade Oppenheimer Perform → Outperform
Oct-22-19 Initiated Oppenheimer Perform
Mar-20-19 Upgrade BofA/Merrill Neutral → Buy
Mar-20-19 Upgrade Wells Fargo Market Perform → Outperform
Nov-28-18 Initiated UBS Sell
Nov-07-18 Downgrade BofA/Merrill Buy → Neutral
Nov-06-18 Downgrade JP Morgan Overweight → Neutral
Nov-06-18 Downgrade Morgan Stanley Equal-Weight → Underweight
Oct-19-18 Downgrade Goldman Neutral → Sell
Jul-02-18 Downgrade Morgan Stanley Overweight → Equal-Weight
May-08-18 Reiterated Canaccord Genuity Buy
May-08-18 Downgrade Northland Capital Outperform → Market Perform
May-08-18 Downgrade Wells Fargo Outperform → Market Perform
View All

Nevro Corp Stock (NVRO) Latest News

pulisher
Nov 23, 2024

Nevro Corp. (NYSE:NVRO) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat

Nov 23, 2024
pulisher
Nov 21, 2024

Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y - MSN

Nov 21, 2024
pulisher
Nov 21, 2024

Nevro’s HFX iQ™ Spinal Cord Technology Receives CE Mark Certification in Europe - TechRound

Nov 21, 2024
pulisher
Nov 20, 2024

NVRO Stock Declines Despite Positive Study Data of Nevro1 System - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Nevro Stock May Gain on the CE Mark Certification for HFX iQ - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Nevro secures CE mark for AI-based spinal cord stimulation system - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Nevro’s SI joint fixation system delivers enhanced stability and fusion for patients - Mass Device

Nov 19, 2024
pulisher
Nov 18, 2024

Nevro announces publication of new data on Nevro1 SI Joint Fusion System - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

New Study Demonstrates Multiple Advantages of Nevro1™ | Trending From Our Network - Chicago Star Media

Nov 18, 2024
pulisher
Nov 18, 2024

Nevro Corp announces inducement grants - Medical Buyer

Nov 18, 2024
pulisher
Nov 15, 2024

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Quantisnow

Nov 15, 2024
pulisher
Nov 15, 2024

Engaged Capital LLC Adjusts Its Stake in Nevro Corp - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Additional Shares in Nevro Corp - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Amendment: SEC Form SC 13D/A filed by Nevro Corp. - Quantisnow

Nov 14, 2024
pulisher
Nov 14, 2024

Nevro Corp. Reports Strong Q3 2024 Financial Performance - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Nevro Corp. (NVRO) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

NVRO stock touches 52-week low at $4.35 amid market challenges - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

FY2024 Earnings Forecast for Nevro Issued By William Blair - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Nevro Corp.'s SWOT analysis: stock faces headwinds amid market challenges - Investing.com Australia

Nov 14, 2024
pulisher
Nov 14, 2024

Analysts Are Updating Their Nevro Corp. (NYSE:NVRO) Estimates After Its Third-Quarter Results - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Nevro wins CE mark for spinal cord stimulation technology - BioWorld Online

Nov 13, 2024
pulisher
Nov 13, 2024

FY2026 Earnings Estimate for Nevro Issued By William Blair - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Nevro stock price target cut, retains hold rating on earnings release - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Nevro Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Nevro Corp’s Market Cap Challenges: Impairment Risks and Investor Concerns - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

Nevro Corp stock target cut, keeps underweight rating on Q3 results - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro wins CE mark for HFX iQ spinal cord stim for pain relief - Mass Device

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro price target raised to $6 from $5 at Baird - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro stock price target cut, retains underweight on earnings beat - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Why Medical Device Firm Nevro Stock Is Trading Higher On TuesdayNevro (NYSE:NVRO) - Benzinga

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro (NYSE:NVRO) Price Target Cut to $7.00 by Analysts at Canaccord Genuity Group - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro's (NVRO) "Sector Perform" Rating Reiterated at Royal Bank of Canada - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Peeling Back The Layers: Exploring Nevro Through Analyst Insights - Benzinga

Nov 12, 2024
pulisher
Nov 12, 2024

Piper Sandler Cuts Nevro (NYSE:NVRO) Price Target to $6.00 - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro Corp. (NYSE:NVRO) Q3 2024 Earnings Call Transcript - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro (NYSE:NVRO) Price Target Raised to $6.00 - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro Corp stock target upgraded, neutral rating on margin outlook By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro Corp (NVRO) PT Lowered to $6 at Piper Sandler - StreetInsider.com

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro receives CE Mark Certification in Europe for HFX iQ SCS System - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro Corp (NVRO) PT Raised to $6 at Baird - StreetInsider.com

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally - PR Newswire

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro Corp (NVRO) PT Lowered to $7 at Canaccord Genuity - StreetInsider.com

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro price target lowered to $6 from $7 at Piper Sandler - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro Corp earnings beat by $0.40, revenue topped estimates - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Nevro stock price target cut, retains underweight on earnings beat By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

Nevro Corp. Shows Resilience Amidst Revenue Challenges - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Nevro: Q3 Earnings Snapshot - CT Insider

Nov 11, 2024
pulisher
Nov 11, 2024

Nevro Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2024 - Marketscreener.com

Nov 11, 2024

Nevro Corp Stock (NVRO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices STE
$217.47
price up icon 0.65%
medical_devices ZBH
$112.02
price up icon 1.25%
medical_devices PHG
$27.15
price up icon 0.89%
$78.10
price up icon 0.21%
$83.00
price up icon 0.59%
medical_devices EW
$72.07
price up icon 0.73%
Cap:     |  Volume (24h):